- Home
- IMTX vs EYPT Comparison
IMTX vs EYPT Comparison
Compare IMTX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- EYPT
- Stock Information
- Founded
- IMTX 2000
- EYPT 1987
- Country
- IMTX Germany
- EYPT United States
- Employees
- IMTX N/A
- EYPT N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- IMTX Health Care
- EYPT Industrials
- Exchange
- IMTX Nasdaq
- EYPT Nasdaq
- Market Cap
- IMTX 653.9M
- EYPT 741.0M
- IPO Year
- IMTX N/A
- EYPT 2005
- Fundamental
- Price
- IMTX $6.00
- EYPT $13.60
- Analyst Decision
- IMTX Strong Buy
- EYPT Strong Buy
- Analyst Count
- IMTX 4
- EYPT 6
- Target Price
- IMTX $14.67
- EYPT $25.83
- AVG Volume (30 Days)
- IMTX 804.7K
- EYPT 767.8K
- Earning Date
- IMTX 08-13-2025
- EYPT 11-06-2025
- Dividend Yield
- IMTX N/A
- EYPT N/A
- EPS Growth
- IMTX N/A
- EYPT N/A
- EPS
- IMTX N/A
- EYPT N/A
- Revenue
- IMTX $152,823,253.00
- EYPT $51,898,000.00
- Revenue This Year
- IMTX N/A
- EYPT N/A
- Revenue Next Year
- IMTX N/A
- EYPT N/A
- P/E Ratio
- IMTX N/A
- EYPT N/A
- Revenue Growth
- IMTX 83.61
- EYPT 2.99
- 52 Week Low
- IMTX $3.30
- EYPT $3.91
- 52 Week High
- IMTX $13.09
- EYPT $14.42
- Technical
- Relative Strength Index (RSI)
- IMTX 53.92
- EYPT 65.67
- Support Level
- IMTX $5.68
- EYPT $12.88
- Resistance Level
- IMTX $6.01
- EYPT $14.42
- Average True Range (ATR)
- IMTX 0.32
- EYPT 0.78
- MACD
- IMTX 0.05
- EYPT 0.05
- Stochastic Oscillator
- IMTX 77.87
- EYPT 74.05
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.